The Outcomes of Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules
Launched by CHINESE PLA GENERAL HOSPITAL · Mar 31, 2024
Trial Information
Current as of September 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a treatment called ultrasound-guided thermal ablation for people with benign thyroid nodules, which are non-cancerous lumps in the thyroid gland. The goal is to see how effective this treatment is and to develop a tool using artificial intelligence that can help predict how well it works for patients. The trial is currently recruiting participants aged 65 to 74, and it is open to all genders.
To be eligible for the trial, participants must have had two tests confirming that their nodules are benign and show no signs of cancer on ultrasound. They should also be experiencing cosmetic concerns or symptoms from the nodules, or they may be unsuitable for surgery. Participants will need to be followed for at least six months after treatment. Those with certain conditions, like findings of cancer on biopsy or specific ultrasound characteristics that suggest malignancy, will not be eligible. If you join this trial, you can expect to receive the thermal ablation treatment and be monitored for your outcomes over time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \[1\]confirmation of benign nodule status on two separate fine- needle aspiration (FNA) or core-needle biopsy (CNB) \[2\]no suspicious malignant features on ultrasound examination \[3\]report of cosmetic and/ or symptomatic problems or concern of nodules growing rapidly or malignant transformation \[4\]refusal or ineligibility for surgery \[5\]follow-up time ≥6months
- Exclusion Criteria:
- • 1. follicular neoplasm or malignancy findings on biopsy
- • 2. nodules with benign result on biopsy had suspicious of malignancy in US, including marked hypoechoic, ill-defined margins, taller-than-wide shape or microcalcifications
- • 3. patients with cystic nodules
- • 4. patients with contra-lateral vocal cord par- alysis
- • 5. previous radiation to the head and neck
- • 6. ; follow- up time less than 6 months
About Chinese Pla General Hospital
The Chinese PLA General Hospital, a prominent military medical institution in Beijing, serves as a leading sponsor for clinical trials, focusing on advancing healthcare through innovative research and development. Renowned for its comprehensive medical services and cutting-edge research capabilities, the hospital is committed to improving patient outcomes through rigorous scientific investigation and collaboration with various stakeholders in the healthcare sector. With a multidisciplinary approach and a strong emphasis on evidence-based practices, the Chinese PLA General Hospital aims to contribute significantly to the global medical community by facilitating the development of safe and effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported